MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer
A Feasibility Study of MRI in Assessment of Primary Tumor During Chemoradiation for Anal Canal and Perianal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- histological confirmation of invasive primary squamous cell carcinoma or adenocarcinoma of the anal canal or perianal region
- treatment with curative intent
- patients who are not eligible for chemotherapy and receive IMRT alone are eligible for evaluation
- primary anal or perianal cancer evaluable on cross-sectional imaging (CT or MRI) scan
- ECOG performance status of 0, 1, or 2
- age > 18 years
- able to provide informed consent
Exclusion Criteria:
- evidence of distant metastasis (M1)
- prior radiation therapy to the pelvis or contraindication to radiotherapy
- contraindication to MRI imaging
- known allergy to intravenous Gadolinium
- renal insufficiency (serum creatinine greater than 150)
- serious claustrophobia
- cardiac pacemaker
- hip prosthesis
- major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of imaging study
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
MRI Scan
|
This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT).
Each imaging session will last for approximately 45 to 60 minutes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary tumor dimensions at simulation and during week 3 and last week of fractionated radiotherapy from MRI
Time Frame: 12 months
|
12 months
|
|
Primary tumor perfusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI
Time Frame: 12 months
|
12 months
|
|
Primary tumor apparent diffusion coefficient at simulation and during week 3 and last week of fractionated radiotherapy from MRI
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change with time from start of radiotherapy course in primary tumor dimensions from MRI
Time Frame: 12 months
|
12 months
|
|
Change with time from start of radiotherapy course in primary tumor perfusion coefficient from MRI
Time Frame: 12 months
|
12 months
|
|
Change with time from start of radiotherapy course in primary tumor apparent diffusion coefficient from MRI
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Robert Dinniwell, MD, University Health Network, Princess Margaret Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UHN REB 09-0695-CE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.